Report: Houston is primed for a boom in these life science subsectors

by the numbers

According to a new report, Houston has potential to lead three life science subsectors: cell and gene therapy manufacturing, molecular diagnostics, and biologics drug development and manufacturing. Photo via Getty Images

A new report found that Houston has great potential across a handful of life science subsectors.

The study by Newmark Consulting Group was commissioned by the Greater Houston Partnership and sponsored by San Jacinto College, Lone Star College, Houston Community College, and McCord Development. It looked at the region's existing resources and value proposition in the life sciences sector.

According to the report, Houston is home to industry-leading expertise in three subsectors: cell and gene therapy manufacturing, molecular diagnostics, and biologics drug development and manufacturing.

From a workforce perspective, the city has a steady flow of new talent from regional universities and "an emerging and robust commitment by community colleges to support two-year degree pathways to meet industry demands and the ability for life science companies to grow and thrive in the market," per the report. The findings led to identifying the next steps for the Houston region to capitalize on these advantages.

“The Newmark study confirms what we knew to be true about the potential for life sciences growth in Houston,” says Susan Davenport, GHP's chief economic development officer, in a news release. “The study will help us coalesce our regional partners around a cohesive strategy to grow and expand the industry in Houston.”

The report's other key findings included:

  • Houston consistently ranks as a top-15 market for life sciences employment nationwide and first in Texas with nearly 700 life science companies operating in town.
  • The Bayou City has the densest patient population in the world, which allows for transformational clinical applications.
  • The city's diverse workforce, extensive university ecosystem, education infrastructure, and research institutions sets a scene for Houston to capture extensive subsector gains.
  • Houston ranks second in the nation in clinical trial volume with more than 4,600 currently active clinical trials, which is representing 15 percent of all active U.S. trials.
  • In 2021, Houston-area institutions attracted $864.1 million in grant funding from the National Institutes of Health, which is up 16.3 percent from 2020. On average over the past five years, the region received $740.7 million per year in NIH funding for a total of $3.9 billion.
  • Houston is home to more than 26,000 non-healthcare life science employees.
  • The region's life sciences workforce ranks No. 12 in the nation, on par with numbers reported for Research Triangle Park.
In light of the report, the GHP is recommending a few action items, including "accelerating workforce development programs to produce new graduates in key life sciences occupations, refining Houston’s marketing messages to highlight the region’s existing life science assets and activities within life science R&D and manufacturing," per the report. Additionally, the GHP identified the need to develop a shared regional strategy to attract and retain leading life sciences companies.
To lead these initiatives, the GHP has assembled task forces, which will be led by the organization’s Life Sciences Committee, chaired by Ferran Prat, senior vice president of Industry Relations and Research at MD Anderson Cancer Center.
Houston — home to the largest medical center — ranks No. 13 on a list of top life science labor markets. Photo via TMC

Here's how Houston ranks as a life science market, according to a new report

by the numbers

For Houston’s life sciences sector, 13 is a very lucky number.

The Houston metro area ranks 13th in CBRE’s first-ever analysis of the country’s top 25 U.S. labor markets for life sciences. Houston’s collective brain power helped cement its place on the list.

The Boston-Cambridge area tops the ranking. Houston is the highest-ranked Texas market, ahead of No. 16 Dallas-Fort Worth and No. 18 Austin.

Dallas-based CBRE, a provider of commercial real estate services, lauds Houston for its “attractive combination” of affordability and a deep pool of Ph.D.-level talent, as well as the presence of major research universities and medical institutions.

Scott Carter, senior vice president of life sciences and healthcare in CBRE’s Houston office, says those factors make Houston “an attractive market for life sciences industry expansion.”

“Houston is projected to lead the nation in population growth over the next five years, which will only strengthen the appeal of its labor market,” Carter says.

Houston boasts the nation’s highest wages in the life sciences sector compared with the cost of living, the analysis shows. Meanwhile, Ph.D. recipients account for 18.5 percent of the 1,300 biological and biomedical sciences degrees granted each year in the Houston area — the highest concentration nationwide. And Houston produces 4.2 percent of such Ph.D. recipients in the U.S. — more than all but a few major life sciences markets do.

“Millions of square feet and billions of dollars of life sciences development is underway or planned in Houston to break down longtime silos between commercial, academic, and medical sectors,” Carter says. “Leveraging the unmatched scale of the Texas Medical Center, these new moon-shot investments are building a launchpad to rocket Space City into a new era as a global hub for scientific and human progress.”

Underscoring the rapid rise of the city’s innovation ecosystem, Houston enjoys one of the country’s fastest-growing pipelines for VC funding in life sciences. Here, VC funding in the sector rose 937 percent in the past five years, compared with the nationwide increase of 345 percent, according to CBRE.

For its analysis, CBRE assessed each market based on several criteria, including its number of life sciences jobs and graduates, its share of the overall job and graduate pool in life sciences, its number of Ph.D. recipients in life sciences, and its concentration of jobs in the broader professional, scientific, and technical services professions.

In 2020, CBRE ranked Houston as the No. 2 emerging hub for life sciences in a report, which factored in size and growth of life-sciences employment, the venture capital and National Institutes of Health funding, and more.

Atul Varadhachary, managing partner of Fannin Innovation Studio, says that now is the time to invest in life sciences. Photo via Getty Images

Innovation studio aims to put Houston on the map for life science startup development

fostering innovation

In a report last year from commercial real estate services company JLL, Boston took the crown for hosting the country's top life sciences ecosystem. Houston ranked 11th.

The difference between Houston and Boston "is not the innovation, it's not the technology, it's not the money. It's that we don't have experienced life sciences entrepreneurs," says Dr. Atul Varadhachary, managing partner of Houston's Fannin Innovation Studio, a for-profit entity that commercializes biotech and medtech concepts.

Fannin has tried to replicate Boston's robust life sciences ecosystem "in a really, really tiny way" via its fellowship program, Varadhachary says. But the reach of the program could be even greater, he believes.

Varadhachary makes a case for tripling or even quadrupling the number of participants in Fannin's federally accredited fellowship program. He says this one relatively small investment could push Houston closer to Boston in the life sciences stratosphere.

Atul Varadhachary is the managing partner of Houston's Fannin Innovation Studio. Photo via fannininnovation.com

To be sure, Houston is no slouch in life sciences. For instance, commercial real estate services company CBRE issued a report last fall ranking Houston second among the country's top emerging clusters for life sciences. But cities like Boston, San Francisco, and San Diego still reign as life sciences royalty in the U.S.

Fannin typically taps five people at a time — folks who've recently earned a master's degree, medical degree or PhD — for a two-year fellowship in life sciences entrepreneurship and commercialization. The initiative is comparable to a post-doctorate program in research or medicine. The Fannin fellows collaborate with therapeutics and medical device companies in the studio's portfolio, gaining hands-on training in facets of business like R&D, intellectual property, regulatory matters, and financing.

Today, five fellows and seven interns work at Fannin. The fellowship program launched in 2006; the internship program started a year earlier. In all, Fannin has welcomed more than 250 fellows and interns. Some of them have gone on to work at Houston organizations such as TMC Innovation, MD Anderson Cancer Center, and the University of Houston.

Varadhachary believes boosting the fellowship headcount to perhaps 15 instead of the current five would be a small price to pay to help elevate Houston's status in life sciences. The full cost of each fellowship is less than $100,000 a year, so bringing aboard another 10 fellows would require an extra annual commitment of under $1 million. That kind of money isn't in Fannin's budget, though.

"I can think of nothing that could give a bigger return on investment for the city," Varadhachary says of expanding Fannin's fellowship program.

More fellows would mean more entrepreneurs equipped to run or start life sciences businesses in Houston, he says. Varadhachary acknowledges the value of efforts like the soon-to-open TMC3 life sciences hub and the recently opened Ion entrepreneurship hub, but he'd like to see more emphasis placed on nurturing people and not just startups.

Varadhachary says the "the one single thing" that Houston could do to increase its probability of success in life sciences, particularly in therapeutics, would be to crank up cultivation of entrepreneurial talent.

"By and large, I don't think know that this community appreciates how important and how under-resourced that whole people-development piece is," he says. "It's not something that comes from taking classes or watching. It comes from doing."

Andrea Letkeman, director of professional development at Fannin, says the fellows initially work one-on-one with a senior executive on projects, then eventually graduate to running their own projects. Fellows also get a close-up look at other projects underway at Fannin.

Varadhachary wants to get Fannin fellows excited "about what we're doing in Houston, and then give them an opportunity to be part of our ecosystem."

Some Fannin fellows have been hired on a full-time basis by the studio, or they've moved into jobs at venture capital firms, life sciences startups, or other players in the ecosystem, according to Letkeman. She says the fellows lend "energy and vibrancy" to Fannin.

"I think that the Fannin model is fairly unique for Houston. There are models that are similar, across the country, to what we do. But there's not enough of them, quite frankly, for the number of people that are interested in these kinds of roles," Letkeman says.

"There is talent that is looking for a way to bridge the gap between academia and real-world commercialization," she adds. "There's just not enough opportunities out there for them."

Kevin Coker, CEO of Proxima Clinical Research, say his company transform from uncertainty to almost uncontrollable growth in just 12 months. He shares what happened on this week's episode of the Houston Innovators Podcast. Photo courtesy of Proxima

Houston health tech company bounces back from COVID-19 in a big way

HOUSTON INNOVATORS PODCAST EPISODE 82

The pandemic hit life science innovation hard. And no one knows that better than Kevin Coker, co-founder and CEO of Proxima Clinical Research, a Houston-based contract research organization focused on supporting life science startups as they grow and scale.

"Last year from January to June, it was very tough," Coker says on this week's episode of the Houston Innovators Podcast. "Hospitals shut down, so any existing projects we had ongoing just halted."

Coker and his team of 12 — including co-founder and chairman, Larry Lawson — at the time didn't have any new projects coming in and were at the mercy of the pandemic.

"Everything was flat. In May, I was starting to worry. I didn't know how long we were going to have to weather the storm," Coker remembers.

Then, in June, things started changing, he says. As hospitals started to reopen and clinical research was reignited. Initially, some COVID diagnostic products were gaining momentum, as well as some emergency use authorization products.

"Things just really started taking off for us," Coker says. "I think it was really a product of investors and people being able to make decisions despite the pandemic."

Coker describes the experience not as a rollercoaster — it was all downhill for Proxima and then business took flight. Last quarter, the company was signing a new contract every two to three days. With the influx of projects, Coker says his team scaled to 50 full time employees and 75 part time team members — most of these new additions Coker hasn't even met yet, since the staff has been working remotely.

"We're a good barometer for what's happening not only locally but across the country," Coker says. "As Proxima has grown, it's really show how the Houston life science market is growing."

Now, Coker is focused on maintaining the company culture at Proxima as well as finding a new, larger office space in the Texas Medical Center — Proxima's current office is in the TMC Innovation Institute.

Coker says it's his intention to keep its operations smaller and more hands on than the usual CRO, which typically has 5,000 to 10,000 employees and multi-billion dollars in revenue, and focused on startups and small companies.

"That type of organization doesn't work well with a small med device or pharmaceutical company. We wanted to create a company that looked and felt like the startups," he says.

Coker shares more about Proxima's growth and Houston's potential of being a major life science hub on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston’s 10 most valuable startups revealed in new report

by the numbers

The Greater Houston Partnership has released its list of the 10 most valuable startups that are fueling the city’s growth and entrepreneurial energy, including industry giants like Axiom Space and Fervo Energy.

Currently, Houston hosts more than 1,300 startups in industries such as energy, life sciences, manufacturing and aerospace, according to the GHP. The list ranks its top 10 startups by valuation based on the company’s last private funding round, reflected in Pitchbook data, as of Oct. 20 of this year.

The top 10 list includes:

10. NXTClean Fuels

Valuation: $530 million

NXTClean Fuels builds biofuel refineries that produce renewable fuel by using feedstocks like cooking oil and recycled organic materials.

9. Homebase

Valuation: $660 million

HR tech company Homebase provides employee management software that helps manage and optimize timesheets, payroll and more, with over over 100,000 small businesses and 2 million hourly workers using its product.

8. Zolve

Valuation: $800 million

Zolve is a banking platform that provides customers with access to financial products that aim to be accessible, flexible, and affordable than other financial platforms.

7. Stramsen Biotech

Valuation: $807 million

Stramsen Biotech develops plant-based drug therapies that target both infectious and noninfectious diseases, which include cancer, diabetes, HIV, kidney disease and neurological issues.

6. Octagos

Valuation: $843 million

Healthtech company Octagos has developed a remote cardiac monitoring software driven by AI that helps consolidate patient data in real-time, assisting healthcare professionals in providing quicker, easier and more accurate care.

5. Fervo Energy

Valuation: $1.4 billion

Pioneering geothermal company Fervo Energy combines horizontal drilling and fiber-optic sensing to produce electricity. The company is developing its flagship Cape Station geothermal power project in Utah. The first phase of the project will supply 100 megawatts of power beginning in 2026

4.Cart.com

Valuation: $1.7 billion

Cart.com is an e-commerce giant and logistics solutions provider that was founded in 2020 and obtained unicorn status within just three years.

3. Axiom Space

Valuation: $2.1 billion

Axiom Space is one of the anchor tenants at the Houston Spaceport, and has completed four missions of sending commercial astronauts to the ISS since 2022. In 2027, the company expects to see the first section of its private space station, Axiom Station, launched into low-earth orbit.

2. Solugen

Valuation: $2.175 billion

Solugen replaces petroleum-based products with plant-derived substitutes through its Bioforge manufacturing platform.

1. HighRadius

Valuation: $3.2 billion

HighRadius uses advanced technology to automate and manage accounts receivable processes for businesses worldwide.

The GHP also released its State of Houston’s Tech and Innovation Landscape, which mapped Houston’s digital and innovation sectors. Read the full report here.

Photos: Highlights from the 2025 Houston Innovation Awards

Innovation Awards Recap

The 2025 Houston Innovation Awards season came to a close on Nov. 13 at InnovationMap's annual awards program and networking event.

The fifth annual Houston Innovation Awards celebrated more than 40 innovative finalists and crowned 10 winners across prestigious categories. In the weeks leading up to the event, finalists were profiled in our editorial series spotlights. Read all about this year's winners here.

Finalists, judges, and special guests connected during an exclusive VIP reception before the doors officially opened for the evening. A full house of attendees then gathered to celebrate the best and brightest in Houston innovation right now. The night culminated in an awards program, emceed this year by Lawson Gow, Greentown Labs Head of Houston.

Scroll through the photos below for scenes from the event, including the winners, the guests, and more highlights from the program.

Special thanks to this year's sponsors for an unforgettable evening honoring Houston innovation: Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, William Price Distilling, and Citizens Catering.

2025 Houston Innovation Awards Winners:

Energy Transition Business of the Year: Eclipse Energy. Photo by Emily Jaschke
2025 Houston Innovation Awards Winners:

2025 Houston Innovation Awards Winners, Continued

Minority-founded Business of the Year: Mars Materials. Photo by Emily Jaschke

2025 Houston Innovation Awards Guests 

Photo by Emily Jaschke

More 2025 Houston Innovation Awards Highlights

Photo by Emily Jaschke

Texas ranks among 10 best states to find a job, says new report

jobs report

If you’re hunting for a job in Texas amid a tough employment market, you stand a better chance of landing it here than you might in other states.

A new ranking by personal finance website WalletHub of the best states for jobs puts Texas at No. 7. The Lone Star State lands at No. 2 in the economic environment category and No. 18 in the job market category.

Massachusetts tops the list, and West Virginia appears at the bottom.

To determine the most attractive states for employment, WalletHub compared the 50 states across 34 key indicators of economic health and job market strength. Ranking factors included employment growth, median annual income, and average commute time.

“Living in one of the best states for jobs can provide stable conditions for the long term, helping you ride out the fluctuations that the economy will experience in the future,” WalletHub analyst Chip Lupo says.

In September, Gov. Greg Abbott announced Texas led the U.S. in job creation with the addition of 195,600 jobs over the past 12 months.

“Texas is America’s jobs leader,” Abbott says. “With the best business climate in the nation and a skilled and growing labor force, Texas is where businesses invest, jobs grow, and families thrive. Texas will continue to cut red tape and invest in businesses large and small to spur the economic growth of communities across our great state.”

While Abbott proclaims Texas is “America’s jobs leader,” the state’s level of job creation has recently slowed. In June, the Federal Reserve Bank of Dallas noted that the state’s year-to-date job growth rate had dipped to 1.8 percent, and that even slower job growth was expected in the second half of this year.

The August unemployment rate in Texas stood at 4.1 percent, according to the Texas Workforce Commission. Throughout 2025, the monthly rate in Texas has been either four percent or 4.1 percent.

By comparison, the U.S. unemployment rate in August was 4.3 percent, according to the U.S. Bureau of Labor Statistics. In 2025, the monthly rate for the U.S. has ranged from 4 percent to 4.3 percent.

Here’s a rundown of the August unemployment rates in Texas’ four biggest metro areas:

  • Austin — 3.9 percent
  • Dallas-Fort Worth — 4.4 percent
  • Houston — 5 percent
  • San Antonio — 4.4 percent

Unemployment rates have remained steady this year despite layoffs and hiring freezes driven by economic uncertainty. However, the number of U.S. workers who’ve been without a job for at least 27 weeks has risen by 385,000 this year, the Bureau of Labor Statistics reported in August. That month, long-term unemployed workers accounted for about one-fourth of all unemployed workers.

An August survey by the Federal Reserve Bank of New York showed a record-low 44.9 percent of Americans were confident about finding a job if they lost their current one.
View All Listings